Abbott
Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
Published in Surgery Litigation and Law Weekly, December 4th, 2009
Abbott (NYSE:ABT) announced three-year data from the first 30 patients in the first phase of the ABSORB clinical trial, demonstrating that its fully bioabsorbable drug eluting coronary stent successfully treated coronary artery disease and was absorbed into the walls of treated arteries. Patients in this first phase of the ABSORB trial experienced no stent thrombosis (blood clots) out to three years and no new major adverse cardiac events (MACE(1)) between six months and three years (3.6 percent at three years). These results were presented at the 2009 American Heart Association's Scientific Sessions.
To build upon the promising results of the ABSORB trial, Abbott is...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
More Articles from Surgery Litigation and Law Weekly
- ACLU of Illinois
Reversing Two Restrictive Policies, Illinois Issues Accurate Birth Certificates to Three Transgender Persons - CCH, a Wolters Kluwer business
CCH Briefing Details Tax Provisions of Senate, House Health Care Reform Bills - High-Tech Institute
High-Tech Institute Kansas City to Offer Six New Associate of Science Degree Programs - Robinson, Calcagnie & Robinson
Robinson, Calcagnie & Robinson Announces That California Court Has Certified Class Action Lawsuit Against Abbott Medical Optics - Abdominal Aortic Aneurysm
New abdominal aortic aneurysm study findings have been reported by scientists at Shanghai Jiao Tong University - Abscess
Research data from P. Tabrizian and colleagues update understanding of abscess - More from this issue of Surgery Litigation and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
